SOUTH EASTON, Mass., March 19, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the commercial release of the Barocycler HUB880, the newest addition to the Company's growing line of high-pressure instrument systems. The Company also announced the sale (and shipment) of its first HUB880 system to Dr. Wayne Hubbell of the University of California Los Angeles (UCLA). PBI plans to showcase the HUB880 at the upcoming U.S. Human Proteome Organization's 10th Annual Conference to be held at the Westin-Seattle (WA), April 6-9, 2014.
The Barocycler HUB880 is an automated, computer-controlled, bench-top, ultra-high pressure instrument. It was designed to have a safe and reproducible operating range from approximately 1,000 psi to approximately 100,000 psi (about 7,000 times normal atmospheric pressure). The Company believes that these features will make the Barocycler HUB880 an instrument of choice for a broad range of studies that can utilize the special effects of ultra-high pressure on biological and other samples.
The Company believes that there are approximately 500,000 scientists worldwide working with biological samples, such as animal, plant, microbial, and human cells. These cells, and the biomolecules that constitute them (e.g., proteins, lipids, DNA) have historically been controlled (e.g., modified, inactivated, manipulated) using temperature and chemicals. However, studies have shown that cells/biomolecules also respond to specific levels of pressure in unique and reproducible ways. Thus, with its ability to reach ultra-high pressure levels significantly beyond any automated bench-top pressure instrument commercially available today, the Company believes that the Barocycler HUB880 can potentially offer scientists the unique ability to control certain cells and biomolecules in ways never before achievable.
Dr. Wayne L. Hubbell, Distinguished Professor of Chemistry and Biochemistry and Jules Stein Professor of Ophthalmology at UCLA, commented: "The unique capabilities of the Barocycler HUB880 will allow us to explore 'invisible' states of proteins – that is, protein states not detectable at normal atmospheric pressure but only at ultra-high pressure. We are excited by this possibility since these invisible states are very likely important to protein structure and function and may reveal new targets for future drug design."
Dr. Nathan P. Lawrence, Vice President of Sales and Marketing, said: "Our existing high pressure instruments, with upper pressure limits ranging from 35,000 to 58,000 psi, satisfy very important needs in today's demanding research environment. As such, we believe the sales increases observed in 2013 with our HUB440, NEP2320, NEP3229, and Constant Systems instruments and consumables will continue into 2014, and will be augmented with sales from the new additions to our product line."
Dr. Lawrence continued: "We also believe that the enhancements built into the new Barocycler HUB880 instrument system – most especially the increased upper pressure limit of 100,000 psi – will allow researchers to extend their high pressure studies well beyond where they are today. This will allow them, for the very first time, to safely investigate the benefits of ultra-high pressure (60,000 psi and above) in a number of new, yet to be tried, biological, chemical, material, and industrial sciences applications. We are particularly excited that the HUB880 can reach pressures sufficient to kill most pathogenic and food-borne bacteria. We believe this capability may allow the HUB880 to play an important role in additional vaccine, diagnostic, therapeutic, and food safety research, which we believe will result in a continued increase in the number of high pressure instrument systems and consumables sold in 2014 and beyond."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our proprietary technology – pressure cycling technology. PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterrorism applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter
Richard T. Schumacher, President & CEO, PBI
(508) 230-1828 (T)
Howard Gostfrand, President, American Capital Ventures
(305) 918-7000 (T)
SOURCE Pressure BioSciences, Inc.